Paper17538157
Epidermal growth factor receptor inhibition in head and neck cancer--more insights, but more questions.
Forastiere AA and 1 other. J Clin Oncol, 2007. Cited by 39 papers, by iCite.
Cite this record
ConductScience Library. Epidermal growth factor receptor inhibition in head and neck cancer--more insights, but more questions. Papers, record 17538157. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/17538157
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- Epidermal growth factor receptor inhibition in head and neck cancer--more insights, but more questions.
- PubMed
Topics12
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Antibodies, Monoclonal | Major topic |
| Carcinoma, Squamous Cell | Major topic |
| ErbB Receptors | Major topic |
| Head and Neck Neoplasms | Major topic |
| Quinazolines | Major topic |
| Antibodies, Monoclonal, Humanized | |
| Cetuximab | |
| Erlotinib Hydrochloride | |
| Gene Dosage | |
| Humans | |
| Polymerase Chain Reaction | |
| Quality of Life |
Source PubMed
Comments and corrections5
PubMed's comments and corrections, NLM's own indexing: retractions first, then expressions of concern, errata and updates, and comments last.
| Kind | PMID | Title | In Papers | Source |
|---|---|---|---|---|
| Comment on | 17538160 | Epidermal growth factor receptor copy number alterations correlate with poor clinical outcome in patients with head and neck squamous cancer. | https://conductscience.org/library/papers/17538160 | PubMed |
| Comment on | 17538161 | Open-label, uncontrolled, multicenter phase II study to evaluate the efficacy and toxicity of cetuximab as a single agent in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck who failed to respond to platinum-based therapy. | https://conductscience.org/library/papers/17538161 | PubMed |
| Comment on | 17538162 | Phase I/II trial of erlotinib and cisplatin in patients with recurrent or metastatic squamous cell carcinoma of the head and neck: a Princess Margaret Hospital phase II consortium and National Cancer Institute of Canada Clinical Trials Group Study. | https://conductscience.org/library/papers/17538162 | PubMed |
| Comment on | 17538163 | Predictive and pharmacodynamic biomarker studies in tumor and skin tissue samples of patients with recurrent or metastatic squamous cell carcinoma of the head and neck treated with erlotinib. | https://conductscience.org/library/papers/17538163 | PubMed |
| Comment on | 17538164 | Quality of life in head and neck cancer patients after treatment with high-dose radiotherapy alone or in combination with cetuximab. | https://conductscience.org/library/papers/17538164 | PubMed |
Cited by13
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 39 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 36579667 | EGF‑IL2 bispecific and bivalent EGF fusion toxin efficacy against syngeneic head and neck cancer mouse models. | Oncol Rep | 2023 | https://conductscience.org/library/papers/36579667 | PubMed |
| 33540470 | A novel diphtheria toxin-based bivalent human EGF fusion toxin for treatment of head and neck squamous cell carcinoma. | Mol Oncol | 2021 | https://conductscience.org/library/papers/33540470 | PubMed |
| 29230548 | Quality of life of patients with locally advanced head and neck cancer treated with induction chemotherapy followed by cisplatin-containing chemoradiotherapy in the Dutch CONDOR study: a randomized controlled trial. | Support Care Cancer | 2018 | https://conductscience.org/library/papers/29230548 | PubMed |
| 28810546 | Changes in cell junctions induced by inhibition of epidermal growth factor receptor in oral squamous cell carcinoma cells. | Exp Ther Med | 2017 | https://conductscience.org/library/papers/28810546 | PubMed |
| 26883159 | Interaction of EGFR to δ-catenin leads to δ-catenin phosphorylation and enhances EGFR signaling. | Sci Rep | 2016 | https://conductscience.org/library/papers/26883159 | PubMed |
| 25622907 | RhoC mediates epidermal growth factor-stimulated migration and invasion in head and neck squamous cell carcinoma. | Neoplasia | 2015 | https://conductscience.org/library/papers/25622907 | PubMed |
| 24602316 | MiRNA-125a-5p: a regulator and predictor of gefitinib's effect on nasopharyngeal carcinoma. | Cancer Cell Int | 2014 | https://conductscience.org/library/papers/24602316 | PubMed |
| 23599382 | Deficiency of renal cortical EGF increases ENaC activity and contributes to salt-sensitive hypertension. | J Am Soc Nephrol | 2013 | https://conductscience.org/library/papers/23599382 | PubMed |
| 22851748 | Enterococcus faecalis enhances cell proliferation through hydrogen peroxide-mediated epidermal growth factor receptor activation. | Infect Immun | 2012 | https://conductscience.org/library/papers/22851748 | PubMed |
| 20302655 | Epidermal growth factor receptor regulates beta-catenin location, stability, and transcriptional activity in oral cancer. | Mol Cancer | 2010 | https://conductscience.org/library/papers/20302655 | PubMed |
| 20158573 | Oncologist's/haematologist's view on the roles of pathologists for molecular targeted cancer therapy. | J Cell Mol Med | 2010 | https://conductscience.org/library/papers/20158573 | PubMed |
| 19216848 | Immunotherapy of head and neck cancer using tumor antigen-specific monoclonal antibodies. | Curr Oncol Rep | 2009 | https://conductscience.org/library/papers/19216848 | PubMed |
| 18577994 | Combined effects of bevacizumab with erlotinib and irradiation: a preclinical study on a head and neck cancer orthotopic model. | Br J Cancer | 2008 | https://conductscience.org/library/papers/18577994 | PubMed |
Genes1
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
| Gene | NCBI Gene ID | Linked by | In Genes |
|---|---|---|---|
| EGFR | 1956 | PubTator's text mining | https://conductscience.org/library/genes/1956 |
Source NCBI Gene
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- References
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/17538157
GET https://conductscience.org/api/papers/v1/17538157/authors